Why RenovoRx, Inc.’s (RNXT) Stock Is Up 5.60%
As of Tuesday, October 20, RenovoRx, Inc.’s RNXT share price has surged by 5.60%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Commentary & Analysis
Why RenovoRx, Inc.’s (RNXT) Stock Is Up 6.25%
As of Thursday, October 15, RenovoRx, Inc.’s RNXT share price has surged by 6.25%, which has investors questioning if this is right time to sell.Michael Rose
Why RenovoRx, Inc.’s (RNXT) Stock Is Down 5.76%
As of Wednesday, October 07, RenovoRx, Inc.’s RNXT share price has dipped by 5.76%, which has investors questioning if this is right time to buy.Jenna Brashear
Why RenovoRx, Inc.’s (RNXT) Stock Is Down 7.85%
As of Monday, October 05, RenovoRx, Inc.’s RNXT share price has dipped by 7.85%, which has investors questioning if this is right time to buy.Jenna Brashear
Why RenovoRx, Inc.’s (RNXT) Stock Is Down 6.33%
As of Monday, September 28, RenovoRx, Inc.’s RNXT share price has dipped by 6.33%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | RNXT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $57.3 | $229.3 | 18% |
|
| Shares Out (Mil) | 47.3 | 53.4 | 46% |
|
| Institutional Ownership | 75.6% | 92.9% | 46% |
|
| Float (Mil) | 39.2 | 41.4 | 41% |
|
| Beta | 0.99 | 0.94 | 59% |
|
| Avg Daily Volume (000s) | 441 | 533 | 57% |
|
| Price Change (52-week) |
6.7% | 47.5% | 58% |
|
| Growth | RNXT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (24.1%) | (10.1%) | 17% |
|
| EPS (5yr) | 28.7% | 15.8% | 80 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 14.9% | (15.7%) | 72% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 2 | |
| Current EPS | ($0.050) | ($0.270) | ($0.120) | |
| Month Ago EPS | ($0.050) | ($0.270) | ($0.120) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.075) | ($0.310) | ($0.150) | |
| Year/Year Chg | (19.4%) | (14.6%) | (125.3%) | |
| Financials | RNXT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $37 | 3% |
|
| Net Income (TTM) (Mil) | ($12) | ($44) | 28% |
|
| EPS (TTM) | ($0.310) | ($1.600) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($34) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 13% |
|
| Enterprise Value (Q1) (Mil) | $44 | $179 | 15% |
|
| Valuation | RNXT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.35 | 2.17 | 84% |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | RNXT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 84.4% | 66.0% | 91% |
|
| Net Margin | (621.7%) | (75.3%) | 1% |
|
| ROA | (97.8%) | (47.1%) | 6% |
|
| ROE | (125.2%) | (53.5%) | 7% |
|
| Liabilities to Assets | 21.7% | 29.3% | 14% |
|
| F-Score | 1 | 2 | 1% |
|
RenovoRx, Inc. did not pass any screens on 10/22/2026.
